Discover
KLRS
Kalaris Therapeutics, Inc.
2.36
2 x 3.12
2 x 5.60
bid
ask
-
0.14
5.60%
2 @ 04:26 PM
2.36 +0.00 (0.00%)
| Ytd | -72.04% | |
| 1y | -49.03% |
2.36
day range
2.55
2.36
52 week range
10.98
| Open | 2.46 | Prev Close | 2.50 | Low | 2.36 | High | 2.55 | Mkt Cap | 56.18M |
| Vol | 104.43K | Avg Vol | 252.89K | EPS | -1.95 | P/E | N/A | Forward P/E | N/A |
| Beta | 0.42 | Short Ratio | N/A | Inst. Own | N/A | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-07 | 50-d Avg | 3.57 | 200-d Avg | 5.96 | 1yr Est | 0.00 |
| Income Statement | |||
| Operating Expenses | 12.39M | ||
| Research and Development Expense | 9.02M | ||
| Selling, General and Administrative Expense | 3.37M | ||
| Operating Income | -12.39M | ||
| Net Income | -11.51M | ||
| Net Income Common Stock | -11.51M | ||
| Net Income Common Stock (USD) | -11.51M | ||
| Consolidated Income | -11.51M | ||
| Earnings per Basic Share | -0.48 | ||
| Earnings per Basic Share (USD) | -0.48 | ||
| Earnings per Diluted Share | -0.48 | ||
| Earning Before Interest & Taxes (EBIT) | -11.51M | ||
| Earning Before Interest & Taxes (USD) | -11.51M | ||
| Weighted Average Shares | 23.80M | ||
| Weighted Average Shares Diluted | 23.80M | ||
| Balance Sheet | |||
| Cash and Equivalents | 43.67M | ||
| Cash and Equivalents (USD) | 43.67M | ||
| Investments | 50.37M | ||
| Investments Current | 50.37M | ||
| Current Assets | 95.92M | ||
| Property, Plant & Equipment Net | 1.39M | ||
| Total Assets | 99.54M | ||
| Debt Current | 347.00K | ||
| Total Debt | 1.40M | ||
| Current Liabilities | 8.74M | ||
| Debt Non-Current | 1.05M | ||
| Total Liabilities | 41.87M | ||
| Accumulated Retained Earnings (Deficit) | -182.37M | ||
| Accumulated Other Comprehensive Income | -73.00K | ||
| Shareholders Equity | 57.67M | ||
| Shareholders Equity (USD) | 57.67M | ||
| Assets Non-Current | 3.62M | ||
| Total Debt (USD) | 1.40M | ||
| Liabilities Non-Current | 33.13M | ||
| Trade and Non-Trade Payables | 1.12M | ||
| Cash Flow | |||
| Depreciation, Amortization & Accretion | 53.00K | ||
| Net Cash Flow from Financing | -377.00K | ||
| Net Cash Flow / Change in Cash & Cash Equivalents | 8.75M | ||
| Issuance (Purchase) of Equity Shares | 10.00K | ||
| Net Cash Flow from Investing | 20.17M | ||
| Net Cash Flow - Investment Acquisitions and Disposals | 20.17M | ||
| Net Cash Flow from Operations | -11.05M | ||
| Share Based Compensation | 644.00K | ||